Mostrar o rexistro simple do ítem

dc.contributor.authorGomez Rial, Jose 
dc.contributor.authorCurras-Tuala, M J
dc.contributor.authorTalavero González, Cristina 
dc.contributor.authorRodríguez-Tenreiro, C
dc.contributor.authorVilanova Trillo, Lucía
dc.contributor.authorGómez Carballa, Alberto
dc.contributor.authorRivero Calle, Irene 
dc.contributor.authorJusticia Grande, Antonio José 
dc.contributor.authorPardo Seco, Jacobo José
dc.contributor.authorRedondo Collazo, Lorenzo 
dc.contributor.authorSalas, A.
dc.contributor.authorMartinón Torres, Federico 
dc.date.accessioned2017-09-05T10:17:54Z
dc.date.available2017-09-05T10:17:54Z
dc.date.issued2017
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/?term=28558652es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/9462
dc.description.abstractThe IFI27 interferon gene expression has been found to be largely increased in rotavirus (RV)-infected patients. IFI27 gene encodes for a protein of unknown function, very recently linked to epidermal proliferation and related to the epidermal growth factor (EGF) protein. The EGF is a low-molecular-weight polypeptide that is mainly produced by submandibular and parotid glands, and it plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. Our aim was to determine salivary EGF levels in RV-infected patients in order to establish its potential relationship with IFI27 increased expression and EGF-mediated mucosal protection in RV infection. We conducted a prospective comparative study using saliva samples from 27 infants infected with RV (sampled at recruitment during hospital admission and at convalescence, i.e. at least 3 months after recovery) and from 36 healthy control children. Median (SD) EGF salivary concentration was 777 (529) pg/ml in RV-infected group at acute phase and 356 (242) pg/m at convalescence, while it was 337 (119) pg/ml in the healthy control group. A significant association was found between EGF levels and hospitalization length of stay (P-value = 0.022; r(2) = -0.63). The salivary levels of EGF are significantly increased during the acute phase of natural RV infection, and relate to length of hospitalization. Further assessment of this non-invasive biomarker in RV disease is warranted.es
dc.description.sponsorshipInstituto de Salud Carlos IIIes
dc.description.sponsorshipXunta de Galicia. Consellería de Sanidadees
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshRotavirus*
dc.subject.meshEpidermal Growth Factor*
dc.subject.meshSaliva*
dc.subject.meshConvalescence*
dc.titleSalivary epidermal growth factor correlates with hospitalization length in rotavirus infectiones
dc.typeArtigoes
dc.rights.holderLos autoreses
dc.identifier.doi10.1186/s12879-017-2463-0
dc.identifier.essn1471-2334
dc.identifier.pmid28558652
dc.issue.number1es
dc.journal.titleBMC Infectious Diseaseses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostelaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Análise clínicoses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Pediatríaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial370es
dc.relation.projectIDInstituto de Salud Carlos III/(Proyecto de Investigación en Salud, Acción Estratégica en Salud): project GePEM ISCIII/ PI16/01478/Cofinanciado FEDER) (A.S.)es
dc.relation.projectIDInstituto de Salud Carlos III/Rotanext ISCIII/PI13/02382 and ReSVinext ISCIII/PI16/01569/Cofinanciado FEDER (F.M.T.)es
dc.relation.projectIDConsellería de Sanidade, Xunta de Galicia/ (RHI07/2-intensificación actividad investigadora, PS09749 and 10PXIB918184PRes
dc.relation.projectIDFondo de Investigación Sanitaria (FIS; PI070069/PI1000540) del plan nacional de I + D + I y ‘ fondos FEDER ’ (F.M.T.es
dc.relation.projectID2016-PG071 Consolidación e Estructuración REDES 2016GI-1344 G3VIP (Grupo Gallego de Genética Vacunas Infecciones y Pediatría, ED341D R2016/021)(A.S. and F.M.es
dc.relation.projectIDInstituto de Salud Carlos III/ (Intensificación de la actividad investigadora 2007 – 2012, PI16/01569)es
dc.relation.publisherversionhttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2463-0es
dc.rights.accessRightsopenAccesses
dc.subject.decsconvalecencia*
dc.subject.decsRotavirus*
dc.subject.decssaliva*
dc.subject.decsfactor de crecimiento epidérmico*
dc.subject.keywordBiomarkerses
dc.subject.keywordBiomarcadoreses
dc.subject.keywordEGFes
dc.subject.keywordIFI27es
dc.subject.keywordRotavirus infectiones
dc.subject.keywordInfección por rotaviruses
dc.subject.keywordTiempo de hospitalizaciónes
dc.subject.keywordTempo de hospitalizaciónes
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number17es


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional